ArriVent BioPharma (AVBP) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 14.6% versus a loss of 46.6%. ArriVent BioPharma is the larger company by market cap ($821.5 million vs $568.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | DBVT |
|---|---|---|
| Share price | $16.66 | $9.05 |
| Market cap | $821.47M | $568.78M |
| 1-day change | -0.77% | -0.66% |
| YTD return | -17.20% | -52.79% |
| 1-year return | -14.61% | -46.61% |
| 5-year return | — | -18.03% |
| EPS (TTM) | $-3.62 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.64M |
| Revenue growth (YoY) | — | +35.77% |
| Net income (latest FY) | $-166.31M | $-146.95M |
| Operating margin | — | -2609.23% |
| Net margin | — | -2607.29% |
| 52-week high | $35.83 | $26.19 |
| 52-week low | $11.36 | $8.63 |
| Distance from 52-week high | -53.50% | -65.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +29.41% | +328.07% |
| Average volume | 1.00M | 350.73K |
| Shares outstanding | 49.31M | 62.85M |
| Employees | 77 | 170 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed DBVT by 32.0 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Healthcare · Biotechnology · 77 employees
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
AVBP vs DBVT FAQ
Which is bigger, ArriVent BioPharma or DBV Technologies S.A.?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $821.47M compared with $568.78M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, AVBP or DBVT?
AVBP returned -14.61% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.